Tagged with China

Hong Kong With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the opening of a new Advanced Therapy Products (ATP) Good Manufacturing Practice (GMP) Centre earlier this month.   Leveraging the city’s…

Hong Kong Hong Kong’s Secretary for Innovation, Technology and Industry since July 2022, Professor Dong SUN is a pioneer in robotic manipulation of biological cells and robot control, whose research has led to breakthroughs in the use of robotics combined with various micro-engineering tools. Now with responsibility for developing Hong Kong into…

Hong Kong Former chief executive of the Hong Kong Special Administrative Region (HKSAR) Leung Chun-ying (CY Leung) discusses recent science and technology initiatives like the new Hong Kong University of Science and Technology campus in Guangzhou and the Hong Kong-Shenzhen Innovation and Technology Park, which is set to further foster cooperation between…

China A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political tensions – China remains an attractive market for multinational pharma.   AstraZeneca defies geopolitics to bet on China – Financial…

China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…

China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre.   COVID global emergency over but risks remain, says China health official (Reuters)…

China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…

Hong Kong In 2022, the biotech sector felt the impact of the challenges facing global capital markets and Hong Kong was no exception. Last year, only eight biotech companies listed on the Stock Exchange of Hong Kong Limited (HKEX), raising an aggregate of USD 473 million. Nonetheless, Hong Kong continues to serve…

China The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China, how the country’s drug pricing policy is impinging biotech profits, and the ways in which COVID-19 exposed the weaknesses in…

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…

China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…